Idraparinux

Idraparinux

File:Idraparinux.png
Systematic (IUPAC) name
Nonasodium (2S,3S,4S,5R,6R)-6-[(2R,3R,4S,5R,6R)-6- [(2R,3S,4S,5R,6R)-2-carboxylato- 4,5-dimethoxy-6-[(2R,3R,4S,5R,6S)-6-methoxy-4,5- disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl] oxyoxan-3-yl]oxy-4,5-disulfonatooxy- 2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-dimethoxy- 3-[(2R,3R,4S,5R,6R)-3,4,5-trimethoxy- 6-(sulfonatooxymethyl)oxan-2-yl]oxyoxane- 2-carboxylate
Clinical data
Routes of administration	Subcutaneous
Legal status
Legal status	Investigational
Pharmacokinetic data
Biological half-life	80-130 hours
Identifiers
CAS Number	149920-56-9
ATC code	none
PubChem	CID 3083444
Chemical data
Formula	C38H55Na9O49S7
Molar mass	1727.17683 g/mol[[]]

Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.

It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours), which means that the drug should only need to be injected once a week.

As of July 2007, it has completed the Phase III clinical trial AMADEUS.

Method of action

Idraparinux selectively blocks coagulation factor Xa.

See Heparin: Mechanism of anticoagulant action for a comparison of the mechanism of heparin, low-molecular-weight heparins, fondaparinux and idraparinux.

References

pt:Idraparinux